Pioneering Advancements in the Pulmonary
senior management team and the Board of Directors have in-depth expertise
and experience in the management and oversight of public health care
companies and in bringing a variety of pharmaceutical and health care
products to market in the U.S.
and internationally. Members of the company's Scientific Advisory Board are
among the world's leading experts in pulmonary medicine and inhalation drug
delivery. Together, this leadership team is pioneering important
advancements in the respiratory sector of the pharmaceutical industry and
positioning Aradigm as a new leader in the specialty pharmaceutical market.
The Board of Directors appointed Dr. John
Siebert, Chairman of the Board of the Company,
as Executive Chairman and Interim Principal
Executive Officer of the Company. Dr. Siebert
has served as a director of the Company since
Dr. Siebert was Chief Executive Officer of Chase
Pharmaceuticals, a company conducting clinical
trials in Alzheimer’s disease based on a unique
hypothesis from May 2014 to November 2015.
From 2010 to 2014, he was a Partner and Chief
Operating Officer of New Rhein Healthcare
Investors, LLC, a private equity group. From
May 2003 to October 2008, Dr. Siebert was the
Chairman and Chief Executive Officer of CyDex,
Inc., a privately held specialty pharmaceutical
company. From September 1995 to April 2003,
he was President and Chief Executive Officer of
CIMA Labs, Inc., a publicly traded drug delivery
company, and from July 1995 to September
1995 he was President and Chief Operating
Officer of CIMA Labs. From 1992 to 1995, Dr.
Siebert was Vice President, Technical Affairs at
Dey Laboratories, Inc., a privately held
pharmaceutical company. From 1988 to 1992,
Dr. Siebert headed R&D and Quality Control at a
division of Bayer Corporation. Prior to that, Dr.
Siebert was employed by E.R. Aquibb & Sons,
Inc., G.D. Searle & Co., Gillette and The Procter
& Gamble Company. Dr. Siebert holds a B.S. in
Chemistry from Illinois Benedictine University,
an M.S. in Organic Chemistry from Wichita
State University and a Ph.D. in Organic
Chemistry from the University of Missouri. Dr.
Siebert also serves on the Board of Directors of
Supernus Pharmaceuticals, Inc., serving as a
member of the Audit Committee and the Chair
of the Compensation Committee.
David Cipolla, Ph.D.
Vice President Preclinical R&D
Cipolla holds a chemical engineering degree from MIT (S.B.)
and UC Davis (M.S.) and a pharmacy degree from the
University of Sydney (Ph.D.). Dr. Cipolla currently leads
the preclinical research,
pharmaceutical sciences and intellectual property efforts at
Aradigm Corp and has served in various scientific and
technical capacities at Aradigm since 1996.
Prior to joining Aradigm, Dr. Cipolla worked at
Genentech, Inc. (1988-1996) developing and characterizing
the delivery of protein aerosols to the airways, culminating
with the approval of Pulmozyme® rhDNase for the management
of cystic fibrosis. Dr.
Cipolla has contributed in a number of roles on
pharmaceutical consortia (including chair of IPAC-RS),
academic societies (ISAM board member) and on the editorial
board of multiple scientific journals.
Janice Dahms, M.S.
Vice President Project Management
Ms. Dahms has more than 25 years of industry experience in
product development and project, portfolio and alliance
management. Prior to joining Aradigm, she served as
Executive Director of Product Development at Intarcia
Therapeutics, Senior Director of Project Management at
Abgenix, and held project management and clinical operations
positions at ALZA, PAREXEL and Bristol-Myers Squibb. She has
experience leading projects from early through late stages
of development and played a key role in the approval of 6
marketed products. Ms. Dahms built the project management
organizations at Intarcia and Abgenix to address their
individual needs which included oversight of outsourced
work, interfaces with development partners and evaluation of
potential new projects. Ms. Dahms is a graduate of Boston
University and earned her M.S. in Pharmacology from the
University of Chicago.
Board of Directors
Virgil D. Thompson
Chairman of the Board, Aradigm Corporation;
CEO of Spinnaker Biosciences, Inc.
Dr. John M. Siebert
Former Chairman & Chief Executive Officer, CyDex, Inc.;
Former CEO of CIMA Labs
Director of Supernus
Former partner of KPMG, LLP
Executive Vice President of Grifols, Inc.
President Global Marketing of Grifols, Inc.
Aradigm's Scientific Advisory Board is a highly
regarded team of scientific experts who help the Company with strategic
input into the development of treatments for severe respiratory disease,
and in pharmaceutical development and pulmonary drug delivery in general.
The group assists the company on a variety of issues related to potential
product applications, product development paths and clinical testing.
Peter R. Byron, Ph.D.
Medical College of Virginia,
Virginia Commonwealth University
Expertise: Aerosol Science/Pharmaceutics
Stephen J. Farr,
Expertise: Pulmonary Delivery/Pharmaceutics
Tunde Otulana , M.D.
Expertise: Pulmonary Medicine,
Adam Wanner, Ph.D.
University of Miami
Expertise: Chronic Obstructive Pulmonary Disease (COPD)
addition to this Scientific Advisory Board, the Company also engages other
scientific and medical experts to assist on issues specific to particular indications